Evaluation of the effect and safety of recombinant human erythropoietin (ior ®EPOCIM ) as a cardioprotective agent in the surgery of rheumatic valvular disease.

Center of Molecular Immunology (CIM), Havana0 个研究点目标入组 30 人开始时间: 2013年8月26日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

•1. Patients who require replacement or surgical valve plasty by insufficiency or mitral or aortic stenosis caused by rheumatic fever.
•2. Patients with age = 18 years and = 65 years.
•3. Patients who have signed the informed consent model.
•4. Patients with figures of hemoglobin = 13 g/dL.

•1. Patients with uncontrolled arterial hypertension.
•2. Patients with insulin-dependent diabetes mellitus.
•3. Patients with a known risk or a history of venous or arterial thromboembolic disease.
•4. Patients with a known history of renal failure.
•5. History of cerebrovascular disease.
•6. Oncological diseases.
•7. Patients with known hypersensitivity to products derived from upper cells or human albumin.
•8. Pregnancy or breastfeeding.
•9. Need to replace 2 or more valves or other types of cardiovascular surgery.

发起方

Center of Molecular Immunology (CIM), Havana